CO2023005726A2 - Formulación sólida - Google Patents

Formulación sólida

Info

Publication number
CO2023005726A2
CO2023005726A2 CONC2023/0005726A CO2023005726A CO2023005726A2 CO 2023005726 A2 CO2023005726 A2 CO 2023005726A2 CO 2023005726 A CO2023005726 A CO 2023005726A CO 2023005726 A2 CO2023005726 A2 CO 2023005726A2
Authority
CO
Colombia
Prior art keywords
solid formulation
viral replication
pharmaceutical formulations
active pharmaceutical
pharmaceutical ingredient
Prior art date
Application number
CONC2023/0005726A
Other languages
English (en)
Inventor
Donghua Zhu
Kristof Leonard Kimpe
Sune Klint Andersen
Matthieu Jean M Ravelingien
Ivan Henri M Somers
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CO2023005726A2 publication Critical patent/CO2023005726A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con formulaciones farmacéuticas que comprenden un ingrediente farmacéutico activo; y uno o una combinación de copolímero de ácido metacrílico, o un derivado de celulosa en donde el ingrediente farmacéutico activo es un inhibidor de la replicación viral del dengue. También se describen formas de dosificación sólidas que comprenden dichas formulaciones farmacéuticas, procesos para prepararlas y su uso en métodos de prevención y/o tratamiento y/o inhibición de la replicación viral.
CONC2023/0005726A 2020-11-04 2023-05-05 Formulación sólida CO2023005726A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/126596 WO2022094816A1 (en) 2020-11-04 2020-11-04 Solid formulation
PCT/CN2021/128521 WO2022095913A1 (en) 2020-11-04 2021-11-03 Solid formulation

Publications (1)

Publication Number Publication Date
CO2023005726A2 true CO2023005726A2 (es) 2023-05-29

Family

ID=78649077

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005726A CO2023005726A2 (es) 2020-11-04 2023-05-05 Formulación sólida

Country Status (15)

Country Link
US (1) US20240000749A1 (es)
EP (1) EP4240331A1 (es)
JP (1) JP2023548348A (es)
KR (1) KR20230104226A (es)
CN (1) CN116685317A (es)
AU (1) AU2021376584A1 (es)
CA (1) CA3200538A1 (es)
CO (1) CO2023005726A2 (es)
CR (1) CR20230192A (es)
DO (1) DOP2023000084A (es)
MX (1) MX2023005219A (es)
PE (1) PE20231946A1 (es)
TW (1) TW202233178A (es)
UY (1) UY39503A (es)
WO (2) WO2022094816A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935307C (en) * 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3305289A1 (en) * 2016-10-06 2018-04-11 Philipps-Universität Marburg Usage of silvestrol, episilvestrol and silvestrol analoga for the treatment of viral infections caused by viruses with cap-dependent translation
MX2020002883A (es) * 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composiciones para tratar la infección viral.
US20190365738A1 (en) * 2018-05-21 2019-12-05 Cadila Healthcare Limited Amorphous solid dispersion of valbenazine tosylate and process for preparation thereof
CA3112485A1 (en) * 2018-09-18 2020-03-26 Metacrine, Inc. Crystalline forms of a farnesoid x receptor agonist
KR102173092B1 (ko) * 2018-11-20 2020-11-02 중앙대학교 산학협력단 루테인 장용성 고체분산체를 유효성분으로 함유하는 위산보호용 조성물 및 이를 포함하는 경구용 제제
CN111407728B (zh) * 2020-04-16 2022-02-22 重庆市畜牧科学院 一种替米考星肠溶性固体分散体及其制备方法和应用

Also Published As

Publication number Publication date
AU2021376584A1 (en) 2023-06-29
CA3200538A1 (en) 2022-05-12
MX2023005219A (es) 2023-07-25
KR20230104226A (ko) 2023-07-07
TW202233178A (zh) 2022-09-01
CR20230192A (es) 2023-10-26
EP4240331A1 (en) 2023-09-13
CN116685317A (zh) 2023-09-01
UY39503A (es) 2022-05-31
WO2022094816A1 (en) 2022-05-12
US20240000749A1 (en) 2024-01-04
JP2023548348A (ja) 2023-11-16
PE20231946A1 (es) 2023-12-05
DOP2023000084A (es) 2023-11-15
WO2022095913A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CO2020001743A2 (es) Métodos de tratamiento para la fibrosis quística
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36904A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36903A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI202100047A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE alfa1-ANTITRIPSINA
CO2023005726A2 (es) Formulación sólida
CL2017001913A1 (es) Composición tópica curativa
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
PE20220510A1 (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2020001353A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr.
CL2022000095A1 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
AR120453A1 (es) Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer
CO2020002287A2 (es) Composiciones farmacéuticas
CO2020000292A2 (es) Preparación medicinal combinada para tratar infecciones virales
UA123399U (uk) Фармацевтична композиція холіну альфосцерату у лікарській формі для орального застосування
UA109243U (uk) Тверда лікарська форма, що містить інгібітор віл протеази